Drug companion protocol
Epitalon (Epithalon)
A synthetic tetrapeptide studied for telomerase, circadian, and geroprotective biology in preclinical and limited human literature.
Quickstart Highlights
- Drug class
- Synthetic tetrapeptide
- Route
- Subcutaneous injection
- Schedule
- Editorial research protocol reference describes daily subcutaneous use for a short cycle; no approved human dosing label exists
- Evidence score
- 28
Quickstart highlights
- 💉Subcutaneous injection
- 🔬Synthetic tetrapeptide
- 🧪Lyophilised powder — requires reconstitution with bacteriostatic water
How this works
Mechanism of action and pharmacokinetic profile from published data.
Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) discussed in pineal peptide research. Proposed mechanisms include telomerase activation and modulation of melatonin/circadian pathways, but no regulator-approved human therapeutic protocol exists.
- Time to peak (Tmax)
- Not established.
- Clearance
- Peptide degradation is expected, but a regulator-standard PK profile is not available.
- Elimination half-life
- Not established in an approved human prescribing label.
- Bioavailability
- Editorial protocol pages discuss subcutaneous administration; validated human pharmacokinetic data are limited.
Dosing & Reconstitution Guide
Full preparation, protocol, and administration reference for compounded lyophilised formulations.
Protocol overview
Editorial research protocol reference describes daily subcutaneous use for a short cycle; no approved human dosing label exists.
Dose escalation phases
Editorial Epitalon 10 mg vial reference
| Phase | Dose | Frequency | Guidance |
|---|---|---|---|
| Days 1-20 cycle-on Week 1-3 | 5 mg | once daily | Editorial cycle-on research reference. Not approved dosing. Do not treat as a prescribing protocol. |
| Weeks 4-26 cycle-off Week 4-26 | 0 mg | off-cycle | Editorial off-cycle reference. No approved repeat-cycle schedule exists. |
Supplies needed
- ◦Research vial and diluent — Use the vial size and bacteriostatic water volume described by the applicable research protocol or compounder.
Editorial 10 mg vial protocol (5 mg/mL)
| Phase / Dose | U-100 Units | Volume (mL) |
|---|---|---|
| Days 1-20 cycle-on reference | 100 | 1.00 |
| Cycle-off reference | 0 | 0.00 |
Reconstitution steps
Vial size
10 mg
BAC water to add
2 mL
Resulting concentration
5 mg/mL
At 5 mg/mL, 1 U-100 unit = 0.01 mL = 0.05 mg (50 mcg).
Editorial protocol: add bacteriostatic water slowly down the vial wall, avoid foaming, gently swirl or roll until dissolved, label, protect from light, and refrigerate.
Injection steps
- 1Reconstitute gently
Add diluent slowly down the vial wall, gently swirl or roll until dissolved, and label with date and concentration.
Storage instructions
Before reconstitution
Editorial protocol describes frozen lyophilized storage around -20 C, with routine protection from moisture and light.
After reconstitution
Refrigerate reconstituted solution at 2-8 C and protect from light.
Editorial page describes 2-4 weeks; use stricter compounder or research protocol instructions if supplied.
Important notes
- !Research protocol limitation
This injection guide supports structured API display only and is not a prescribing protocol.
Concentration calculations are standard compounding arithmetic. Protocol phases are drawn from published Phase 2 trial data. Your prescriber and dispensing pharmacy determine the actual dose, vial size, and escalation schedule for your treatment.
Your journey
Where you are in a typical protocol, and what one dose cycle looks like. Educational — your prescriber tailors the plan to you.
Protocol timeline
Cycle-on reference
Weeks 1–35 mgevery 1dWhat to expect: editorial short-cycle protocol reference, sleep/circadian focus discussed in source
Focus on: site rotation, document dose and site, do not treat as prescribing guidance
Common adjustments: no approved adjustment rules exist
Cycle-off reference
Weeks 4–260 mgWhat to expect: editorial off-cycle interval
Focus on: review evidence ceiling, avoid unsupported claims
Common adjustments: repeat cycles are not label validated
Daily companion
Practical playbooks for managing symptoms, eating around side effects, tracking what matters, and reporting back to your clinician.
Food guidance by situation
Prefer: consistent sleep schedule, adequate hydration
Limit: alcohol near bedtime
Avoid: unsupported protocol stacking
The editorial protocol frames Epitalon around sleep/circadian timing; this is contextual lifestyle copy, not prescribing guidance.
What to track
Suggested check-in cadence: daily.
Injection-site reaction
scale 0 10
Energy
scale 0 10
Sleep quality
scale 0 10
Unexpected symptoms
text
Safety and interactions
Share this information with your prescriber for personalised care decisions.
Red-flag symptoms — seek urgent care
- Unexpected systemic reactionUrgent careSeek urgent care for breathing symptoms, swelling, severe dizziness, or a rapidly worsening reaction after an unapproved injectable product.
- Unexpected systemic reaction. Stop use and seek medical advice for rash, swelling, breathing symptoms, severe dizziness, or any concerning reaction after an unapproved injectable product.
Structured warnings
Editorial protocol only
Epitalon has no approved human therapeutic dosing label. The 10 mg vial schedule is an editorial research protocol reference, not a validated prescribing protocol.
Unexpected systemic reaction
Stop use and seek medical advice for rash, swelling, breathing symptoms, severe dizziness, or any concerning reaction after an unapproved injectable product.
Indication and approval status
No approved therapeutic indication represented in this catalogue entry.
No approved prescribing population.
Who should not take this
Epitalon is not approved by major regulators for human therapeutic use. Formal contraindications, dose adjustments, and monitoring requirements have not been established in an approved label. Avoid treating editorial dose tables as validated medical protocols.
Missed-dose guidance
No approved missed-dose rule exists for Epitalon.
Do not double doses based on an editorial schedule; discuss interruptions with a clinician or research supervisor.
When to seek help
Any systemic reaction, severe injection-site reaction, breathing symptom, swelling, or severe dizziness after an unapproved injectable product.
Stop use and contact a clinician; urgent care for breathing symptoms, swelling, or severe systemic reactions.
Approved injection sites
Abdomen
Rotate sites daily and stay at least 2 inches from the navel.
Avoid: Avoid bruised, red, hard, scarred, or irritated skin.
Thigh
Rotate between abdomen and outer thigh areas.
Avoid: Avoid tender, bruised, red, or hardened skin.
Structured storage
research lyophilized vial
before reconstitution
-20 C or refrigerated per supplier protocol
Editorial protocol says protect from moisture and avoid repeated freeze-thaw cycles.
research reconstituted vial
after reconstitution
2-8 C
Editorial page describes 2-4 weeks.
Not an approved label; use stricter compounder or research-protocol instructions.
Storage and handling
No licensed pharmaceutical storage standard exists for research Epitalon preparations. Editorial protocol pages describe frozen lyophilized storage and refrigerated storage after reconstitution, but product quality and sterility depend on the supplier or compounder.
Research evidence
Published studies, labels, regulator pages, and curated protocol sources connected to this profile.
API source references
Epitalon 10 mg vial PeptideDosages protocol
Editorial research protocol page for Epitalon / Epithalon 10 mg vial; not a prescribing label.
Open source ↗Get the full companion experience in Viora
Week-by-week reminders, food and symptom tracking, and the complete companion guide in one place.
Available on iOS and Android.